VYNE - Vyne Therapeutics Inc logo

VYNE

Vyne Therapeutics Inc

Vyne Therapeutics Inc. is a clinical-stage biopharmaceutical company developing therapies for chronic inflammatory and immune-mediated conditions. Its lead product is repibresib gel, a topical BET inhibitor, alongside VYN202, an oral small molecule in trials.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$1,032,203today

Score Overview

1 Year
Score8.4
Net Growth33.52%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth13.77%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.9
Net Growth89.64%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-97.28%
Rev Trend40%
Revenue Consistencyโ€”
All Time
Score3.1
Net Growth48.52%
Net Trend43%
Net Income ConsistencyInconsistent
Rev Growth-94.64%
Rev Trend43%
Revenue Consistency57%

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-07-29
$ 30.45โ€”
5 Years2021-08-06
$ 0.031032x
All Time2018-01-25
$ 0.3293x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 570K-$ 26M$ 29M
2024$ 501K-$ 39M$ 61M
2023$ 424K-$ 28M$ 93M
2022$ 477K-$ 23M$ 30M
2021$ 931K-$ 73M$ 42M
2020$ 20M-$ 255M$ 58M
2019$ 1M-$ 70M$ 76M
IPO2018$ 10M-$ 51M$ 136M